ICON Public (NASDAQ:ICLR) Sets New 1-Year Low at $196.01

Shares of ICON Public Limited (NASDAQ:ICLRGet Rating) hit a new 52-week low during trading on Tuesday . The company traded as low as $196.01 and last traded at $197.00, with a volume of 2232 shares. The stock had previously closed at $201.74.

Analyst Ratings Changes

A number of equities analysts have commented on ICLR shares. UBS Group started coverage on shares of ICON Public in a report on Wednesday, September 7th. They issued a “buy” rating and a $270.00 price objective on the stock. Barclays cut their price objective on shares of ICON Public from $260.00 to $240.00 and set an “equal weight” rating on the stock in a report on Monday, September 12th. William Blair restated an “outperform” rating on shares of ICON Public in a research note on Thursday, July 28th. Deutsche Bank Aktiengesellschaft upped their target price on shares of ICON Public from $285.00 to $295.00 in a research note on Friday, July 29th. Finally, Credit Suisse Group began coverage on shares of ICON Public in a research note on Wednesday, August 24th. They issued a “neutral” rating and a $260.00 target price on the stock. Four research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. According to data from MarketBeat, ICON Public has an average rating of “Moderate Buy” and a consensus target price of $276.70.

ICON Public Stock Down 1.3 %

The company has a debt-to-equity ratio of 0.61, a current ratio of 1.18 and a quick ratio of 1.18. The firm has a market cap of $15.85 billion, a PE ratio of 77.26, a P/E/G ratio of 1.25 and a beta of 0.99. The business has a fifty day moving average price of $222.25 and a two-hundred day moving average price of $224.30.

ICON Public (NASDAQ:ICLRGet Rating) last issued its quarterly earnings results on Wednesday, July 27th. The medical research company reported $2.86 earnings per share for the quarter, beating analysts’ consensus estimates of $2.52 by $0.34. ICON Public had a return on equity of 10.54% and a net margin of 2.77%. The business had revenue of $1.94 billion for the quarter, compared to the consensus estimate of $1.93 billion. During the same quarter in the previous year, the company posted $2.12 earnings per share. ICON Public’s revenue for the quarter was up 122.1% compared to the same quarter last year. On average, analysts anticipate that ICON Public Limited will post 10.61 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of ICLR. Desjardins Global Asset Management Inc. purchased a new position in ICON Public in the second quarter valued at about $61,000. Assetmark Inc. grew its stake in ICON Public by 177.3% in the second quarter. Assetmark Inc. now owns 477 shares of the medical research company’s stock valued at $103,000 after purchasing an additional 305 shares in the last quarter. Steph & Co. grew its stake in ICON Public by 21.5% in the second quarter. Steph & Co. now owns 604 shares of the medical research company’s stock valued at $131,000 after purchasing an additional 107 shares in the last quarter. Harbor Investment Advisory LLC grew its stake in ICON Public by 380.2% in the second quarter. Harbor Investment Advisory LLC now owns 629 shares of the medical research company’s stock valued at $136,000 after purchasing an additional 498 shares in the last quarter. Finally, First Horizon Advisors Inc. grew its stake in ICON Public by 14.5% in the second quarter. First Horizon Advisors Inc. now owns 673 shares of the medical research company’s stock valued at $145,000 after purchasing an additional 85 shares in the last quarter. Hedge funds and other institutional investors own 91.28% of the company’s stock.

ICON Public Company Profile

(Get Rating)

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.

Recommended Stories

Receive News & Ratings for ICON Public Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ICON Public and related companies with MarketBeat.com's FREE daily email newsletter.